YK-2168 / Damei Biopharma, WuXi AppTec - LARVOL DELTA

Discovery and preclinical profile of YK-2168, a differentiated selective CDK9 inhibitor in clinical development. (PubMed, Bioorg Med Chem Lett) - "YK2168 exhibited improved CDK9 selectivity over AZD4573 and BAY1251152; also showed differentiated intravenous PK profile and remarkable solid tumor efficacy in a mouse gastric cancer SNU16 CDX model in preclinical studies. YK-2168 is currently in clinical development in China (CTR20212900)."

Journal • Preclinical • Gastric Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor